발표논문

제목 전이성 대장암 환자에게 표준화된 Rhus verniciflua stokes 추출물의 효과
전이성 대장암 환자에게 표준화된 Rhus verniciflua stokes 추출물의 효과
Impact of standardized Rhus verniciflua stokes extract as complementary therapy on metastatic colorectal cancer: a Korean single-center experience.
저자 Lee SH, Choi WC, Yoon SW
저널명 Integr Cancer Ther
게재일 2009.06
논문소개 BACKGROUND : To investigate the clinical feasibility of the standardized Rhus verniciflua Stokes (RVS) extract for the metastatic colorectal cancer (mCRC), experimentally proven to have anticancer activities.

RESULTS : On October 21, 2008, a total of 26 patients died while the remaining 10 patients were alive with evidence of disease. The median RVS administration period was 2.7 months (95% confidence interval, 1.9-3.5). The median overall survival for the entire population was 10.9 months (95% confidence interval, 5.6-16.1) and 1-year survival rate was 44.4%, which is compatible with external controls. By survival analysis using Cox proportional hazards model, the performance status and the prior chemotherapy regimen number significantly affected overall survival. Adverse reactions to the RVS treatment were mostly mild and self-limiting.

CONCLUSION : Complementary treatment with the standardized RVS extract might be beneficial for patients with mCRC, since it positively affected overall survival without significant side effects. This study suggests that RVS could be a natural anticancer agent candidate for the treatment of colorectal adenocarcinoma.
페이지 URL http://www.ncbi.nlm.nih.gov/pubmed/?term=19679623

목록